# A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

> **NCT00625274** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 100 (estimated)

## Conditions studied

- Heartburn
- Upper Abdominal Pain
- Nausea
- Acid Regurgitation

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Lansoprazole
- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT00625274
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2008-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625274, "A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00625274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*